Generative AI will continue to be a driving force in innovation, but its future must be sustainable by design.

Key Points Alibaba is a Chinese AI stock that's dirt cheap. Meta Platforms is making a huge bet on AI that should pay off ...

Isomorphic Labs, a Google-backed AI company, is set to begin human trials for cancer drugs designed by AI, raising both hope ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

Historian Niall Ferguson warns against unlimited access to AI tools for those under 25, calling it a disaster for brain development.

One of the biggest barriers to the adoption of any new biotechnology tool is validation and regulatory clarity.

At the latest Capitol Weekly-University of California Student and Policy Center conference this week, “California and AI,” ...

As AI becomes central, the ability to ask the right question isn’t just a technical skill but a foundational one.

The goals of this Perspective are threefold: (1) to inform a broad audience, including machine learning (ML) and artificial intelligence (AI) academics and professionals, about synthetic drug ...

Grok 4 is xAI’s most advanced model yet, but early praise is clashing with old scandals and fresh tests of its limits.